Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
1.2% JNJ 10229570-AAA · 1 trial · 1 indication
Change in lesion counts between baseline and end of study
| Arm | Type | Description |
|---|---|---|
| 1.2% Facial Cream | EXPERIMENTAL | 1.2% JNJ 10229570-AAA |
| 2.4% Facial Cream | EXPERIMENTAL | 2.4% JNJ 10229570-AAA |
| 3.6% Facial Cream | EXPERIMENTAL | 3.6% JNJ 10229570-AAA |
| 0% Facial Cream | PLACEBO_COMPARATOR | Vehicle control |
| Name | Type | Description |
|---|---|---|
| 1.2% JNJ 10229570-AAA | DRUG | 1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks |
| 2.4% JNJ 10229570-AAA | DRUG | 2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks |
| 3.6% JNJ 10229570-AAA | DRUG | 3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks |
| Vehicle control | OTHER | Color matched cream vehicle, applied once daily to the face for 12 weeks |
Inclusion Criteria: * 12 years of age or older, with moderate facial acne vulgaris as defined in the protocol * If female of childbearing potential, must take a pregnancy test and have a negative result * Females of childbearing potential must also agree to use an adequate method of birth control, ...
1.2% JNJ 10229570-AAA is an investigational small molecule being developed for the treatment of acne vulgaris. It is a topical formulation currently in Phase 2 clinical development. The drug has been studied in a completed clinical trial involving 431 participants with acne vulgaris.
1.2% JNJ 10229570-AAA is being developed by Bausch Health Companies Inc. (ticker: BHC). The company is conducting clinical research on this investigational dermatology treatment for acne vulgaris.
1.2% JNJ 10229570-AAA is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial for this acne vulgaris treatment has been completed.
1.2% JNJ 10229570-AAA has been studied in one completed Phase 2 clinical trial, identified as NCT01326780. This randomized, double-blind, placebo-controlled study enrolled 431 participants with acne vulgaris in the United States, including individuals aged 12 years and older.
1.2% JNJ 10229570-AAA is a specific formulation of the investigational drug JNJ 10229570-AAA. The 1.2% designation refers to the concentration of the active ingredient in the topical formulation being studied for acne vulgaris.